

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

SUN PHARMACEUTICAL INDUSTRIES LTD.
and
SUN PHARMACEUTICAL INDUSTRIES, INC.,
Petitioners,

v.

NOVO NORDISK A/S,
Patent Owner.

U.S. Patent No. 10,335,462 to Jensen
Issue Date: July 2, 2019
Title: Use of Long-Acting GLP-1 Peptides

Inter Partes Review No. IPR2024-00107

**PETITIONER'S UPDATED MANDATORY NOTICE
UNDER 37 C.F.R. 42.8(a)(3)**

Pursuant to 37 C.F.R. § 42.8(a)(3), the undersigned on behalf of and acting in a representative capacity for Sun Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries Inc. (collectively “Petitioner”), hereby submits the following mandatory change-of-information notices in connection with the petition for inter partes review of U.S. Patent No. 10,335,462, Case IPR2024-00107, to remove Mr. Christopher W. West as backup counsel for Petitioner.

A. Real Parties-In-Interest

In accordance with 37 C.F.R. § 42.8(b)(1), the real parties-in-interest for Petitioner are Sun Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries Inc.

B. Related Matters

In accordance with 37 C.F.R. § 42.8(b)(2), Petitioner is not aware of any reexamination certificates or pending prosecution concerning the ’462 patent. Petitioner is a defendant in the following consolidated litigation involving the ’462 patent:

- *Novo Nordisk Inc. and Novo Nordisk A/S v. Sun Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries, Inc.*, No. 1:22-cv-00296 (D. Del.) (transferred to MDL on August 5, 2022);
- *In re Ozempic (Semaglutide) Patent Litigation*, No. 22-md-3038-CFC (D. Del.); and
- *Novo Nordisk Inc. and Novo Nordisk A/S v. Rio Biopharmaceuticals, Inc. et al.*, No. 1:22-cv-00294 (D. Del.);

In addition, the following litigations also involve the ’462 patent:

- *Novo Nordisk Inc. v. Aurobindo Pharma USA, Inc.*, No. 1:22-cv-00295 (D. Del.) (dismissed on March 28, 2022);
- *Novo Nordisk Inc. v. Rio Biopharmaceuticals, Inc.*, No. 1:22-cv-00294 (D. Del.);
- *Novo Nordisk A/S v. Sun Pharm. Indus. Ltd.*, No. 1:22-cv-00296 (D. Del.);
- *Novo Nordisk Inc. v. Zydus Worldwide DMCC*, No. 1:22-cv-00297 (D. Del.);
- *Novo Nordisk Inc. v. Mylan Pharms. Inc.*, No. 22-cv-01040-CFC (D. Del.)
- *Novo Nordisk Inc. v. Dr. Reddy's Lab's Ltd.*, No. 1:22-cv-00298 (D. Del.); and
- *Novo Nordisk Inc. v. Alvogen, Inc.*, No. 1:22-cv-00299 (D. Del.).

Petitioner is not aware of any other pending litigation, or any pending proceedings in front of the Patent Trial and Appeal Board except for *Mylan Pharmaceuticals Inc. v. Novo Nordisk A/S*, Case No. IPR2023-00724 and *Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd. v. Novo Nordisk A/S*, Case No. IPR2024-00009.

C. Identification of Counsel (37 C.F.R. § 42.8(b)(3))

Lead Counsel	Back-Up Counsel
<p>Brian Sodikoff Reg No. 54,697 Katten Muchin Rosenman LLP 525 West Monroe Street Chicago, IL 60661 Phone: (312) 902-5200 Email: brian.sodikoff@katten.com</p>	<p>Christopher B. Ferenc Reg No. 59,365 Katten Muchin Rosenman LLP 1919 Pennsylvania Ave., N.W. Suite 800 Washington, DC 20006 Phone: (202) 625-3500 Email: christopher.ferenc@katten.com</p>

D. Service Information (37 C.F.R. § 42.8(b)(4))

Petitioner respectfully requests all correspondence be directed to lead counsel and back-up counsel at the contact information provided above.

Respectfully submitted,

Dated: November 21, 2023

By: /Brian Sodikoff/
Brian Sodikoff
Reg No. 54,697
KATTEN MUCHIN ROSENMAN LLP
525 West Monroe Street
Chicago, IL 60661

*Counsel for Petitioner
Sun Pharmaceutical Industries Ltd. and
Sun Pharmaceuticals Industries, Inc.*

CERTIFICATE OF SERVICE

The undersigned certifies that the foregoing Petitioner's Updated Mandatory Notice under 37 C.F.R. 42 were served on Patent Owner as follows:

J. Steven Baughman - steve.baughman@groombridgewu.com
Megan Raymond - megan.raymond@groombridgewu.com
Novo-Semaglutide-IPR@groombridgewu.com

Dated: November 21, 2023

By: /Brian Sodikoff/
Brian Sodikoff
Reg No. 54,697
KATTEN MUCHIN ROSENMAN LLP
525 West Monroe Street
Chicago, IL 60661

*Counsel for Petitioner
Sun Pharmaceutical Industries Ltd. and
Sun Pharmaceuticals Industries, Inc.*